

1 **Frailty is associated with low physical activity and poor sleep quality in patients**
2 **undergoing myeloablative allogeneic hematopoietic cell transplantation:**

3 **A Fitbit® Pilot Study**
4
5

6 Caryn R. Libbert¹, Fiona He², Najla El Jurdi³, Helen Fagrelus⁴, Mark Juckett³, Joseph
7 Maakaron³, William Juckett⁵, Nicholas Evanoff⁵, Donald R. Dengel⁵, Shernan G. Holtan^{3,6}
8
9

10 ¹ University of Minnesota Medical School, Minneapolis, MN

11 ² Allina Health Cancer Institute, Minneapolis, MN

12 ³ Division of Hematology, Oncology, and Transplantation, Department of Medicine, University
13 of Minnesota, Minneapolis, MN

14 ⁴ Clinical Trials Office, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

15 ⁵ School of Kinesiology, University of Minnesota, Minneapolis, MN

16 ⁶ Transplant and Cellular Therapies, Roswell Park Comprehensive Cancer Center, Buffalo, NY
17

18 **ABSTRACT**

19

20 Allogeneic hematopoietic cell transplantation (alloHCT) is a vital therapy for various
21 hematologic diseases, though it demands high physiological resilience. Frailty, a syndrome
22 impacting the body's ability to withstand stress, affects outcomes of alloHCT across all ages.
23 This study examines the relationship between frailty and peri-transplant activity and sleep
24 patterns using Fitbit® devices. In this pilot study, adults scheduled for their first myeloablative
25 alloHCT at the University of Minnesota from June 2022 to January 2023 were included if they
26 had a compatible device for the Fitbit® app. Participants were monitored for activity and sleep
27 from admission to day +30 post-transplant. Frailty was assessed pre-transplant using Fried
28 Phenotype criteria. Data were analyzed for activity and sleep patterns differences among not
29 frail, pre-frail, and frail groups. Nine patients provided sufficient data for analysis, showing
30 significant variances in activity levels and sleep patterns across frailty categories. Not frail
31 patients exhibited significantly higher daily steps and active minutes than pre-frail and frail
32 patients. Not frail patients also had the highest amount of restorative deep and rapid eye
33 movement sleep. Due to Fitbit methodology and likely frequent interruptions, 28% of the days in
34 the first month post-transplant had a recorded sleep time of 0 minutes. Although our sample size
35 was small, our findings underscore the importance of frailty in influencing activity and sleep
36 patterns among alloHCT recipients.

37 **INTRODUCTION**

38

39 Allogeneic hematopoietic cell transplantation (alloHCT) is a critical treatment for various
40 hematologic conditions, replacing diseased marrow with healthy stem cells from a donor.
41 Despite its effectiveness, alloHCT demands significant physiological resilience from patients.
42 Frailty, a syndrome characterized by a reduction in the body's physiologic reserve—the ability to
43 withstand stress and repair tissue damage—is not restricted to older individuals. It also affects
44 younger patients undergoing alloHCT because of underlying disease or treatment-related
45 toxicities, leading to an increased risk of mortality and post-transplant complications (1-3).
46 Frailty presents in physical, psychological, and social dimensions, affecting patients' ability to
47 cope with and recover from alloHCT. Recognizing the importance of monitoring patient well-
48 being during treatment, this study employs Fitbit® devices to measure activityx and sleep
49 patterns—key health indicators during the peri-transplant period (4). While research has
50 established the detrimental effects of frailty on alloHCT outcomes, the specific activity and sleep
51 patterns associated with varying degrees of frailty—not frail, pre-frail, and frail—remain
52 unexplored, particularly in myeloablative alloHCT settings among otherwise fit adults. Our pilot
53 study aims to investigate these patterns, potentially guiding more personalized care to improve
54 quality of life and survival for alloHCT recipients.

55 **METHODS**

56 Patient Selection

57 We included adults (≥ 18 years) scheduled for their first myeloablative alloHCT at the University
58 of Minnesota who had a smartphone or tablet compatible with the Fitbit® app from June 2022 to
59 January 2023. Participants received a Fitbit® Sense device before their alloHCT hospitalization
60 and were advised to stay active by walking within the hospital unit. Access to physical therapists
61 and exercise facilities was provided. The study adhered to IRB approval and HIPAA guidelines,
62 with all participants giving written informed consent.

63

64 Data Collection and Definitions

65 Participants synced their Fitbit® with a PHI-compliant Fitabase® at least weekly. We included
66 data from admission until day +30 post-transplant, considering days with ≥ 10 hours of wear time
67 as evaluable days. Activity was measured via daily steps, active and sedentary time—active time
68 being periods with ≥ 3 METS energy expenditure. Sleep analysis included duration, deep sleep,
69 and REM sleep. Frailty status, assessed pre-transplant using Fried Phenotype criteria (5),
70 categorized individuals as frail (≥ 3 criteria), pre-frail (1-2 criteria), or not frail (no criteria), with
71 data extracted from health records.

72

73 Statistical Methods

74 Descriptive statistics illustrated Fitbit® data by frailty status. Differences between not frail, pre-
75 frail, and frail groups were analyzed using Kruskal-Wallis tests and Dunn's multiple

76 comparisons for post hoc assessments. Smoothing spline regression curves show longitudinal
77 activity and sleep trends. Statistical analyses were completed using JMP Pro 17 (SAS
78 Corporation, Cary, NC) and GraphPad Prism version 9.4.1 (GraphPad Software, Boston, MA).

79

80 **RESULTS**

81 Patient Characteristics

82 Nine patients with adequate data were included in the analysis. Median age was 48 (range 22 to
83 59); five patients were male and four were female. Two patients were categorized as frail, five as
84 pre-frail, and two as not frail prior to alloHCT. Additional patient characteristics are included in
85 Supplemental Table 1. The mean percentage of evaluable days between hospital admission to
86 day +30 was $81\% \pm 22\%$ with a mean wear time of 1307 ± 198 minutes.

87

88 Patterns of Activity

89 Not frail patients had a higher mean of daily steps compared to pre-frail (2.4-fold higher, $8265 \pm$
90 5274 versus 3381 ± 2757 steps, $p < 0.0001$) and frail (4.2-fold higher, 1977 ± 1610 steps, $p <$
91 0.0001). Pre-frail patients had a higher mean of daily steps than frail (1.7-fold higher, $p = 0.0103$,
92 Figure 1a). Not frail patients also had a higher mean of active minutes compared to pre-frail (56
93 ± 49 versus 20 ± 26 minutes, $p < 0.0001$) and frail (25 ± 47 minutes, $p < 0.0001$). There was no
94 significant difference in the mean of active minutes between pre-frail and frail patients
95 ($p > 0.9999$). Not frail patients had a lower mean of sedentary minutes compared to both pre-frail
96 (763 ± 206 versus 884 ± 313 minutes, $p = 0.0064$) and frail (943 ± 422 minutes, $p = 0.0004$).

97 There was no statistically significant difference in the mean sedentary time between pre-frail and
98 frail patients ($p=0.2472$). Maximum sedentary time occurred around day +15 post-transplant
99 (Figure 1c).

100

101 Patterns of Sleep

102 Across all cohorts, there was a median percentage of 67% (range 0% to 100%) of evaluable days
103 including complete sleep data with sleep stages from admission to day +30. Overall, not frail
104 patients had the best sleep quantity and quality (Figure 1b). Not frail patients spent more time in
105 REM sleep compared to pre-frail (52 ± 36 versus 33 ± 39 minutes, $p = 0.0003$) and frail (24 ± 43
106 minutes, $p < 0.0001$). Frail patients spent less time in deep sleep compared to pre-frail (11 ± 19
107 versus 33 ± 34 minutes, $p = 0.0003$) and not frail (35 ± 24 minutes, $p < 0.0001$). There was a
108 median percentage of 28% (range 0% to 58%) of days with zero minutes of time asleep, a
109 median percentage of 36% (range 3% to 87%) of days with zero minutes of time in deep sleep,
110 and a median percentage of 36% (range 0% to 87%) of days with zero minutes of REM sleep as
111 measured by the Fitbit®. The sleep time nadir was also around day +15 post-transplant (Figure
112 1c).

113 **DISCUSSION**

114 Our study delineates the variances in activity and sleep patterns among three distinct frailty
115 phenotypes prior to transplantation. We discovered that patients without frailty exhibit higher
116 daily step counts and more active time than their pre-frail and frail counterparts. Furthermore,
117 individuals classified as frail not only engaged in less physical activity but more surprisingly also
118 experienced diminished durations of restorative deep and REM sleep. The occurrence of days
119 without recorded sleep data suggests that sleep disruptions are prevalent across all patient
120 groups. Such disturbances may be partly explained by the Fitbit®'s methodology, which only
121 logs sleep after an hour without movement and requires a three-hour minimum of sleep data to
122 analyze sleep stages (6, 7). The frequent nighttime awakenings, as reported by El Jurdi et al.,
123 averaging 4.5 interruptions per night, are a probable factor in the poor sleep quality captured in
124 our findings (4).

125

126 Previous research has linked frailty to decreased overall survival, increased non-relapse
127 mortality, and a decline in the quality of life (2, 3, 8, 9). The reduced activity and lack of
128 restorative sleep observed in frail patients are likely contributing to these negative health
129 outcomes. Interventions tailored to the specific aspects of frailty in the elderly have been shown
130 to enhance physical condition, as noted by Cameron et al. (10). This insight opens the possibility
131 of applying similar targeted interventions to alloHCT patients, employing pre-transplant frailty
132 assessments to inform and customize therapeutic strategies, potentially mitigating the impact of
133 frailty on post-transplant recovery and long-term well-being.

134

135 **CONCLUSION**


136 Our study demonstrated a reduced level of physical activity and poor sleep in individuals with
137 frailty undergoing myeloablative alloHCT. Recognizing these differences may allow for
138 development of targeted interventions to reduce disease burdens of care and improve support
139 systems.

140 **FIGURES**

141

142 **Figure 1:** Patterns of (A) activity and (B) sleep based on phenotype of Frailty. The top of the bar
143 represents the mean with error bars representing standard deviation. Longitudinal sedentary time
144 and minutes asleep by transplant date are shown in C, with the line representing the smoothing
145 spline regression curves.

146



147

148 **REFERENCES**

149

- 150 1. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med.*
151 2011;27(1):1-15.
- 152 2. Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic Frailty in
153 Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow
154 Transplant Survivor Study. *JAMA Oncol.* 2016;2(10):1277-86.
- 155 3. Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, et al.
156 Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. *Biol*
157 *Blood Marrow Transplant.* 2019;25(12):2454-60.
- 158 4. El Jurdi N, Nock N, Fu P, Cao S, Cotton JM, Ali N, et al. Physical Activity and Sleep
159 Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A
160 Pilot Study. *Transplant Cell Ther.* 2021;27(6):502.e1-.e6.
- 161 5. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in
162 older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.*
163 2001;56(3):M146-56.
- 164 6. How do I track my sleep with my Fitbit device? [Available from:
165 https://help.fitbit.com/articles/en_US/Help_article/1314.htm?Highlight=sleep%20.]
- 166 7. What should I know about Fitbit sleep stages? [Available from:
167 https://help.fitbit.com/articles/en_US/Help_article/2163.htm?Highlight=sleep%20.]
- 168 8. Mohanraj L, Sargent L, Elswick RK, Toor A, Swift-Scanlan T. Factors Affecting Quality
169 of Life in Patients Receiving Autologous Hematopoietic Stem Cell Transplantation.
170 *Cancer Nurs.* 2022;45(2):E552-E9.
- 171 9. Huan-Tze L, Yun-Ru L, Kuan-Der L, Huey-En T. Frailty in chronic myeloid leukemia:
172 evidence from 2016–2018 Nationwide Inpatient Sample of the US. *BMC Geriatrics.*
173 2023;23(1).
- 174 10. Cameron ID, Fairhall N, Langron C, Lockwood K, Monaghan N, Aggar C, et al. A
175 multifactorial interdisciplinary intervention reduces frailty in older people: randomized
176 trial. *BMC Medicine.* 2013;11(1):65.

177

178

179

